[Treatment of migraine].
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000627:therapeutic use; D000932:Antiemetics / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy* / Q000517:prevention & control*; D011619:Psychotropic Drugs / Q000627:therapeutic use; D012702:Serotonin Antagonists / Q000627:therapeutic use; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D000893:Anti-Inflammatory Agents; D000927:Anticonvulsants; D000932:Antiemetics; D002121:Calcium Channel Blockers; D011619:Psychotropic Drugs; D012702:Serotonin Antagonists; D014662:Vasoconstrictor Agents